In summary, this retrospective cohort study describes the epidemiology and clinical
profile of VTE across different types of cancer among an Asian population. Although the
incidence rate of cancer-related VTE is lower than Caucasians population, it is much
higher than the general Asian population. VTE is not rare in certain cancer including
pancreas, liver, lung cancer, and multiple myeloma. Risk factors for VTE include prior
history of VTE, arterial embolism, hypertension, obesity, rheumatologic diseases,
chemotherapy, combination therapy, and major surgery. The incidence rate of VTE is
highest within 1 year after cancer diagnosis.
High incidence rate of VTE was detected among cancer patients in Taiwan. Clinical
practitioners should carefully monitor patients with cancer for VTE. Adherence to
treatment guidelines was poor in real world. Treatment and prophylaxis of VTE should be
optimized, especially in patients with higher-risk of VTE. Due to the different
epidemiologic profile of VTE in Taiwan compared with Caucasian population, further
investigations are desired to estimate the harms and benefits of anticoagulants treatment
and thromboprophylaxis among Asian cancer patients.
94
References
1. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and
treatment in patients with cancer. J Clin Oncol 2007;25:5490-505.
2. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245-8.
3. Deitcher SR. Diagnosis, Treatment, and Prevention of Cancer-Related Venous Thrombosis. In: Abeloff M, Armitage J, JNiederhuber J, Kastan M, McKenna W, eds. Abeloff's Clinical Oncology. 4 ed; 2008:693-715.
4. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011;117:1334-49.
5. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous
thromboembolism and its effect on survival among patients with common cancers.
Arch Intern Med 2006;166:458-64.
6. Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006;24:1112-8.
7. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous
thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70-6.
8. Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost 2011;9:85-91.
9. Cohen AT. Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery. Thromb Haemost 2010;104:919-30.
10. Lee CH, Lin LJ, Cheng CL, Kao Yang YH, Chen JY, Tsai LM. Incidence and cumulative recurrence rates of venous thromboembolism in the Taiwanese population. J Thromb Haemost 2010;8:1515-23.
11. Lee C-H, Cheng C-L, Lin L-J, Tsai L-M, Yang Y-HK. Epidemiology and Predictors of Short-Term Mortality in Symptomatic Venous Thromboembolism. Circ J
2011;75:1998-2004.
12. Oh SY, Kim JH, Lee KW, et al. Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity. Thromb Res 2008;122:485-90.
13. Koh Y, Bang SM, Lee JH, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol 2010;89:201-6.
95
14. Lee KW, Bang SM, Kim S, et al. The incidence, risk factors and prognostic
implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost 2010;8:540-7.
15. Choi S, Lee KW, Bang SM, et al. Different characteristics and prognostic impact of deep-vein thrombosis / pulmonary embolism and intraabdominal venous thrombosis in colorectal cancer patients. Thromb Haemost 2011;106:1084-94.
16. Yokoyama K, Murata M, Ikeda Y, Okamoto S. Incidence and risk factors for developing venous thromboembolism in Japanese with diffuse large b-cell lymphoma. Thromb Res 2011.
17. Kang MJ, Ryoo BY, Ryu MH, et al. Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience. Eur J Cancer 2012;48:492-500.
18. Jeon HK, Kim DU, Baek DH, et al. Venous thromboembolism in patients with cholangiocarcinoma: focus on risk factors and impact on survival. Eur J Gastroenterol Hepatol 2012;24:444-9.
19. Segal JB, Eng J, Jenckes MW, et al. Diagnosis and treatment of deep venous thrombosis and pulmonary embolism. Evid Rep Technol Assess (Summ) 2003:1-6.
20. Fields JM, Goyal M. Venothromboembolism. Emerg Med Clin North Am 2008;26:649-83, viii.
21. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd.
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93.
22. White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996.
Thromb Haemost 2005;93:298-305.
23. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism.
N Engl J Med 1998;338:1169-73.
24. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657-60.
25. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR,
Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9.
26. White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 2009;123 Suppl 4:S11-7.
27. Stein PD, Kayali F, Olson RE, Milford CE. Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 2004;116:435-42.
96
28. Cheuk BL, Cheung GC, Cheng SW. Epidemiology of venous thromboembolism in a Chinese population. Br J Surg 2004;91:424-8.
29. Molina JA, Jiang ZG, Heng BH, Ong BK. Venous thromboembolism at the National Healthcare Group, Singapore. Ann Acad Med Singapore 2009;38:470-8.
30. Kobayashi T, Nakamura M, Sakuma M, et al. Incidence of pulmonary
thromboembolism (PTE) and new guidelines for PTE prophylaxis in Japan. Clin Hemorheol Microcirc 2006;35:257-9.
31. Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 2009;28:401-9.
32. Anderson FA, Jr., Spencer FA. Risk factors for venous thromboembolism.
Circulation 2003;107:I9-16.
33. Anderson FA, Jr., Wheeler HB. Physician practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg 1992;16:707-14.
34. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd.
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-15.
35. Goldhaber SZ. Deep Venous Thrombosis and Pulmonary Thromboembolism. In:
Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds.
Harrison's Principles of Internal Medicine. 18th ed. New York: McGraw-Hill; 2012.
36. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd.
Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445-53.
37. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism:
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S.
38. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med 2010;38:S495-501.
39. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ, 3rd.
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-8.
40. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006;368:371-8.
41. Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 2011;342:d813.
42. Witt DM, Nutescu EA, Haines ST. Venous Thromboembolism. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A
Pathophysiologic Approach. 8th ed. New York: McGraw-Hill Medical; 2011.
97
43. Blann AD, Lip GY. Venous thromboembolism. BMJ 2006;332:215-9.
44. Streiff MB. Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol 2009;27:4889-94.
45. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH.
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-4.
46. Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer. Thromb Haemost 2007;98:656-61.
47. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent
thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-91.
48. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors:
determination of frequency and characteristics. Thromb Haemost 2002;87:575-9.
49. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006;119:60-8.
50. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH.
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484-90.
51. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.
Cancer 2007;110:2339-46.
52. Cronin-Fenton DP, Sondergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010;103:947-53.
53. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for
chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822-9.
54. Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost 2010;8:1702-9.
55. Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost 2011;9 Suppl 1:316-24.
56. Hammond J, Kozma C, Hart JC, et al. Rates of venous thromboembolism among patients with major surgery for cancer. Ann Surg Oncol 2011;18:3240-7.
57. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg
98
2006;243:89-95.
58. Falanga A. The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest 2009;27:105-15.
59. Huang H, Korn JR, Mallick R, Friedman M, Nichols C, Menzin J. Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database study. J Thromb Thrombolysis 2012.
60. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24.
61. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
JAMA 2008;300:2277-85.
62. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008;6:601-8.
63. Mandala M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007;18:1660-5.
64. Sandhu R, Pan CX, Wun T, et al. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer
2010;116:2596-603.
65. Rodriguez AO, Wun T, Chew H, Zhou H, Harvey D, White RH. Venous thromboembolism in ovarian cancer. Gynecol Oncol 2007;105:784-90.
66. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
67. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653-61.
68. Mandala M, Falanga A, Piccioli A, et al. Venous thromboembolism and cancer:
guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006;59:194-204.
69. National Comprehensive Cancer Network Web site. NCCN clinical pratice guidelines in oncology: Venous Thromboembolic Disease v.2.2011. (Accessed March 30, 2012, at www.ncc.org.)
70. Mandala M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22 Suppl 6:vi85-92.
71. Farge D, Bosquet L, Kassab-Chahmi D, et al. 2008 French national guidelines for
99
the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol 2010;73:31-46.
72. Debourdeau P, Kassab Chahmi D, Le Gal G, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol 2009;20:1459-71.
73. Moll S, Mackman N. Venous thromboembolism: a need for more public awareness and research into mechanisms. Arterioscler Thromb Vasc Biol 2008;28:367-9.
74. Weitz JI. Unanswered questions in venous thromboembolism. Thromb Res 2009;123 Suppl 4:S2-S10.
75. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest
2012;141:e419S-94S.
76. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med
2002;162:1729-35.
77. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
78. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med
2006;119:1062-72.
79. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer:
enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389-96.
80. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes.
Circulation 2003;107:I17-21.
81. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 1997;84:1099-103.
82. Colwell CW, Jr., Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a
low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 1994;76:3-14.
83. Horbach T, Wolf H, Michaelis HC, et al. A fixed-dose combination of low molecular
100
weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement. Thromb Haemost 1996;75:246-50.
84. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005;92:1212-20.
85. Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of venous
thromboembolism occurrence in medical patients among the insured population.
Thromb Haemost 2009;102:951-7.
86. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients:
randomised placebo controlled trial. BMJ 2006;332:325-9.
87. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800.
88. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ.
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9.
89. Hsiao FY, Yang CL, Huang YT, Huang WF. Using Taiwan national health insurance research databases for pharmacoepidemiology research. J Food Drug Anal
2007;15:99-108.
90. National Health Insurance Research Database, Taiwan. Introduction to the National Health Insurance Research Database (NHIRD), Taiwan. (Accessed February 15, 2012, at http://w3.nhri.org.tw/nhird//date_01.html.)
91. Lin LY, Lee CH, Yu CC, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-- a nation wide database analysis.
Atherosclerosis 2011;217:292-5.
92. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011;63:40-6.
93. Chien IC, Lin CH, Chou YJ, Chou P. Prevalence, incidence, and stimulant use of attention-deficit hyperactivity disorder in Taiwan, 1996-2005: a national
population-based study. Soc Psychiatry Psychiatr Epidemiol 2012.
94. Bih SH, Chien IC, Chou YJ, Lin CH, Lee CH, Chou P. The treated prevalence and incidence of bipolar disorder among national health insurance enrollees in Taiwan, 1996-2003. Soc Psychiatry Psychiatr Epidemiol 2008;43:860-5.
95. Parikh S, Shah R, Kapoor P. Portal vein thrombosis. Am J Med 2010;123:111-9.
96. Ponziani FR, Zocco MA, Campanale C, et al. Portal vein thrombosis: Insight into physiopathology, diagnosis, and treatment. World J Gastroentero 2010;16:143-55.
101
97. Cancer Registry Annual Report, 2008, Taiwan. (Accessed 13 June, 2012, at
http://www.bhp.doh.gov.tw/BHPnet/Portal/StatisticsShow.aspx?No=200911300001 .)
98. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients:
results of a record linkage study. J Thromb Haemost 2006;4:529-35.
99. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-20.
100. Kroger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006;17:297-303.
101. Yu YB, Gau JP, Liu CY, et al. A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. Thromb Haemost 2012;108.
102. Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011;70:1083-6.
103. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997;277:642-5.
104. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation
2008;117:93-102.
105. Squizzato A, Ageno W. The 8th American College of Chest Physicians Guidelines – A perspective on venous thromboembolism guidelines. Thromb Haemost 2008.
106. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC medicine 2011;9:1.
107. Matta F, Singala R, Yaekoub AY, Najjar R, Stein PD. Risk of venous
thromboembolism with rheumatoid arthritis. Thromb Haemost 2009;101:134-8.
108. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer. Arch Intern Med 2008;168:2377-81.
109. Trujillo-Santos J, Nieto JA, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008;100:435-9.
110. Akl EA, Labedi N, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane database of systematic reviews (Online) 2011:CD006650.
111. Chang CH, Chen HC, Lin JW, Kuo CW, Shau WY, Lai MS. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal
102
anti-inflammatory drugs: a nationwide case-crossover study in Taiwan.
Pharmacoepidemiol Drug Saf 2011;20:763-71.
112. Chang CH, Lin JW, Chen HC, Kuo CW, Shau WY, Lai MS. Non-steroidal anti-inflammatory drugs and risk of lower gastrointestinal adverse events: a nationwide study in Taiwan. Gut 2011;60:1372-8.
113. Wittkowsky AK, Nutescu EA. Thrombosis. In: Koda-Kimble MA, Young LY, Kradjan WA, et al., eds. Applied therapeutics : the clinical use of drugs. 9th ed.
Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009.
114. Palareti G. Bleeding with anticoagulant treatments. Hamostaseologie 2011;31:237-42.
115. Cohen A, Chiu KM, Park K, et al. Managing venous thromboembolism in Asia:
Winds of change in the era of new oral anticoagulants. Thromb Res 2012.
116. Cattaruzzi C, Troncon MG, Agostinis L, Garcia Rodriguez LA. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database. J Clin Epidemiol
1999;52:499-502.
117. Raiford DS, Perez Gutthann S, Garcia Rodriguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology 1996;7:101-4.
118. Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data.
Pharmacoepidemiol Drug Saf 2012;21:154-62.
119. Deyo RA, Cherkin DC, Ciol MA. Adapting a Clinical Comorbidity Index for Use with Icd-9-Cm Administrative Databases. J Clin Epidemiol 1992;45:613-9.
120. Zhan C, Battles J, Chiang YP, Hunt D. The validity of ICD-9-CM codes in
identifying postoperative deep vein thrombosis and pulmonary embolism. Jt Comm J Qual Patient Saf 2007;33:326-31.
103
Appendix
Appendix 1 ICD-9-CM codes of comorbid diseases and potential risk factors used in this study
Disease Category ICD-9-CM Codes
Hypertension (malignant, benign, unspecified) 401 Essential hypertension
402 Hypertensive heart disease 403 Hypertensive renal disease
404 Hypertensive heart and renal disease 405 Secondary hypertension
401.xx-405.xx
Heart failure (unspecified, left heart, systolic, diastolic) 428.xx Ischemic heart disease
410 Acute myocardial infarction
411 Other acute and subacute forms of ischemic heart disease 412 Old myocardial infarction
413 Angina pectoris
414 Other forms of chronic ischemic heart disease
410.xx-414.xx
410.xx-414.xx